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Signs and Symptoms 
Hemophilia actually comprises 
several genetic abnormalities, resulting 
in altered production of either factors 
VIII (hemophilia A), IX (hemophilia B), 
or XI (hemophilia C) (Stoelting, 2012).  
Factors VIII, IX, and XI are proteins 
manufactured in the liver that are 
necessary in the clotting cascade and 
coagulation (Stoelting, 2012).  
Hemophilia A comprises the largest 
proportion of hemophilia cases, 
approximately 80-85% (Srivastava, A., 
Brewer, A. K., Mauser-Bunschoten, E. P., 
et. al., 2013).  
Hemophilia is a sex-linked recessive 
coagulation disorder that varies in 
severity.  The implications and 
complications of hemophilia can be life 
threatening; pathology is usually 
diagnosed during childhood and 
adequate management is essential in 
maintaining health.  Advanced practice 
nurses treat a variety of hemophilia 
patients in varying roles throughout the 
lifespan as hemostasis is a constant 
physiologic process.  Thorough 
knowledge of the pathophysiology, 
signs/symptoms, and treatment 
modalities related to hemophilia is 
necessary to provide the highest level of 
comprehensive medical care to such 
patients.  Hemophilia care is continued 
throughout the lifespan, and newer 
research indicates that current treatment 
modalities can initiate further 
pathophysiologic processes that can 
require additional medical care and 
vigilance. 
• Common early manifestations are 
easy bruising in infancy with joint 
hematomas, upon development to 
the crawling/walking stages 
(Srivastava, A., Brewer, A. K., 
Mauser-Bunschoten, E. P., et. al., 
2013).  Bleeding can occur in 
multiple sites, and treatment is 
adjusted accordingly. 
•   See Tables 1 and 2 for breakdown 
of possible bleeding sites and their 
prevalence. 
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Serious Life-threatening 
Joints (hemarthrosis) Intracranial 
Muscles, especially deep compartments 
(iliopsoas, calf, and forearm) 
Neck/throat 
Mucous membranes in the mouth, 
gums, nose, and genitourinary tract 
Gastrointestinal 
Table 1. Sites of Bleeding in Hemophilia, from: Srivastava, A., Brewer, A. K., 
Mauser-Bunschoten, E. P., et. al., 2013 
Epidemiologic data suggest hemophilia A generally affects males, as it is a sex 
linked recessive disorder.  Signs and symptoms usually are related to ease of 
bruising/hematoma formation early in the lifespan especially during the 
crawling/walking phase of development (Srivastava, A., Brewer, A. K., Mauser-
Bunschoten, E. P., et. al., 2013).  The majority of cases are hereditarily linked, but 1/3 
of new cases are the result of spontaneous genetic mutation without prior family 
history (Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., et. al., 2013). 
Hemophilia A is a sex linked recessive disorder that affects approximately 1 in 5,000 
male births in Europe and North American (AnaesthesiaUK, 2009).  The portion of the 
gene that correlates to factor VIII production is quite large, and severity of disease is 
linked to the portion of the gene affected; a functional factor VIII level 1% or less than 
normal results from drastic deletions of genetic material (Stoelting, 2012).  
As previously mentioned, factor VIII is a protein produced in the liver that plays a 
major role in the intrinsic pathway of the clotting cascade, and is essential in activating 
factor X which causes the development of prothrombin and thrombin (Hall & Guyton, 
2011).  Without adequate coagulation and clot formation, hemostasis cannot be 
obtained and pathophysiologic bleeding ensues.  Graphic representation of Factor VIII 
involvement in the clotting cascade is as follows in Figure 1.  
Without development of thrombin and eventually fibrin, stable clot formation fails 
to occur as these proteins provide significant structural clot stability (Hall & Guyton, 
2011).  
As is the case with many disease processes, severity of Hemophilia A can be varied 
and directly correlational to the severity of factor VIII deficiency (Srivastava, A., 
Brewer, A. K., Mauser-Bunschoten, E. P., et. al., 2013). Table 3 illustrates the 
relationship of bleeding and factor level.  As stated, factor VIII is critically important to 
the completion of the intrinsic coagulation pathway of hemostasis; without intrinsic 
activation, the sole means of adequate coagulation is dependent upon activation of the 
extrinsic pathway, namely factor VIIa (Hall & Guyton, 2011).  Upon traditional 
laboratory evaluation, the activated prothrombin time is markedly increased as it 
clinically represents adequacy of intrinsic coagulation (Stoelting, 2012). 
Unfortunately, additional pathology, development of factor VIII inhibitor, can 
develop in as many as 30-40% of patients with severe hemophilia A, less than 1% of 
functional factor VIII (Stoelting, 2012).  Factor VIII inhibitors are IgG antibodies 
produced as an immune response to treatment with factor VIII replacement.  Such 
inhibitors attach to factor VIII proteins resulting in its inactivation and hinder 
coagulation (Kasper, 2004).  Source of factor VIII replacement; either plasma derived 
or recombinant generation, does not impact prevalence of inhibitor development 
(Kasper, 2004).  Patients that develop factor VIII inhibitors are classified as either high 
or low responders, which directly correlates to level of inhibitor production (Kasper, 
2004).  Presence and extent of inhibitor development has significant impact upon 
clinical management of patients with hemophilia A (Kasper, 2004). 
Table 2. Approximate Frequency of Bleeding at Different Sites, from: Srivastava, 
A., Brewer, A. K., Mauser-Bunschoten, E. P., et. al., 2013 
Site of Bleeding Approximate Frequency 
Hemarthrosis:  more common in hinged 
joints (ankles, knees, and elbows), less 
common in multi-axial joints (shoulders, 
wrists, and hips) 
70-80% 
Muscle 10-20% 
Other major bleeds 5-10% 
Central nervous system (CNS) <5% 
Underlying Pathophysiology 
Figure 1. Intrinsic Pathway for  Initiating Blood Clotting, from:  Hall & Guyton, 
2011. 
Significance of Pathophysiology 
Severity Clotting Factor 
Level 
Bleeding Episodes 
Severe <1 IU/dL (<0.01 
IU/mL) or <1% of 
normal 
Spontaneous bleeding into joints or muscles, 
predominantly in the absence of identifiable 
hemostatic challenge 
Moderate 1-5 IU/dL (0.01-0.05 
IU/mL) or 1-5% of 
normal 
Occasional spontaneous bleeding; prolonged 
bleeding with minor trauma or surgery 
Mild 5-40 IU/dL (0.05-
0.40 IU/mL) or 5-
<40% of normal 
 
Severe bleeding with major trauma or 
surgery. Spontaneous bleeding is rare. 
Table 3. Relationship of Bleeding Severity to Clotting Factor Level, from: 
Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., et. al., 2013 
Pathophysiology cont. Implications for Nursing Care 
Prophylactic Treatment 
Acute Management of Bleeding 
At Risk Populations 
First line treatment of patients with hemophilia A is intravenous factor VIII 
replacement, and Table 4 represents The World Federation of Hemophilia’s 
recommended initial target factor VIII levels for specific bleeding processes. 
Patients with hemophilia A are generally prophylactically treated with intravenous 
factor VIII with a goal of maintaining factor VIII levels at approximately 1 IU/dL as this 
level is associated with significantly decreased risk of spontaneous bleeding 
(Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., et. al., 2013).  The primary goal 
of hemophilia A treatment through early adulthood is to maintain/preserve 
musculoskeletal function and prevent any other source of major bleeding (Srivastava, 
A., Brewer, A. K., Mauser-Bunschoten, E. P., et. al., 2013). 
Table 4. Suggested Plasma Factor Peak Level and Duration of Administration, 
from: Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., et. al., 2013 
Type of Hemorrhage Desired Level (IU/dL) Duration 
Days 
Joint 10-20 1-2 
Superficial muscle 10-20 2-3 
Deep muscle 20-40 3-5 
CNS/head 50-80 1-3 
Throat/neck 30-50 1-3 
Gastrointestinal 30-50 1-3 
Renal 20-40 3-5 
Surgery (major) 60-80 (pre-op)/30-40 (post-op) 1-3 
Surgery (minor) 40-80 (pre-op)/20-50 (post-op) 1-5 
Additional Considerations/Modalities for Managing  
• If administered factor VIII via plasma or recombinant source fails to increase serum 
factor VIII levels; the patient must be assessed for the presence of 
inhibitors/antibodies (Kasper, 2004). 
• If acute bleeding cannot be controlled by the administration of factor VIII, 
administration of FFP, activated factor VII, and activated prothrombin complex is 
indicated to achieve hemostasis (Kasper, 2004). 
• Tranexamic acid is an adjunct that can be administered, orally or intravenous, in 
addition to factor VIII to promote adequate hemostasis by preventing fibrin 
degradation ((Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., et. al., 2013). 
Conclusion 
Hemophilia A is a disease requiring medical care throughout the lifespan with the 
possibility of acute exacerbations and accompanying serious illness and disability.  As 
advancements in medical treatment occur, vigilance is needed to adequately manage 
such patients and ensure their health and wellness.  Primary treatment is focused on 
replacing Factor VIII levels and constant collaboration amongst the entire healthcare 
team and patient. 
